Advertisement

Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

      Abstract

      Objective

      Surgical treatment of locally advanced non–small cell lung cancer including single or multilevel N2 remains a matter of debate. Several trials demonstrate that selected patients benefit from surgery if R0 resection is achieved. We aimed to assess resectability and outcome of patients with locally advanced clinical T3/T4 (American Joint Committee on Cancer 8th edition) tumors after induction treatment followed by surgery in a pooled analysis of 3 prospective multicenter trials.

      Methods

      A total of 197 patients with T3/T4 non–small cell lung cancer of 368 patients with stage III non–small cell lung cancer enrolled in the Swiss Group for Clinical Cancer Research 16/96, 16/00, 16/01 trials were treated with induction chemotherapy or chemoradiation therapy followed by surgery, including extended resections. Univariable and multivariable analyses were applied for analysis of outcome parameters.

      Results

      Patients’ median age was 60 years, and 67% were male. A total of 38 of 197 patients were not resected for technical (81%) or medical (19%) reasons. A total of 159 resections including 36 extended resections were performed with an 80% R0 and 13.2% pathological complete response rate. The 30- and 90-day mortality were 3% and 7%, respectively, without a difference for extended resections. Morbidity was 32% with the majority (70%) of minor grading complications. The 3-, 5-, and 10-year overall survivals for extended resections were 61% (95% confidence interval, 43-75), 44% (95% confidence interval, 27-59), and 29.5% (95% confidence interval, 13-48), respectively. R0 resection was associated with improved overall survival (hazard ratio, 0.41; P < .001), but pretreatment N2 extension (177/197) showed no impact on overall survival.

      Conclusions

      Surgery after induction treatment for advanced T3/T4 stage including single and multiple pretreatment N2 disease resulted in 80% R0 resection rate and 7% 90-day mortality. Favorable overall survival for extended and not extended resection was demonstrated to be independent of pretreatment N status.

      Graphical abstract

      Key Words

      Abbreviations and Acronyms:

      CT (computed tomography), EFS (event-free survival), HR (hazard ratio), IQR (interquartile range), MPR (major pathologic response), MRI (magnetic resonance imaging), NCCN (National Comprehensive Cancer Network), NSCLC (non–small cell lung cancer), OS (overall survival), OR (odds ratio), pCR (pathological complete response), PET (positron emission tomography), SAKK (Swiss Group for Clinical Cancer Research)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rosell R.
        • Gómez-Codina J.
        • Camps C.
        • Maestre J.
        • Padille J.
        • Canto A.
        • et al.
        A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
        N Engl J Med. 1994; 330: 153-158
        • Roth J.A.
        • Fossella F.
        • Komaki R.
        • Ryan M.B.
        • Putnam Jr, J.B.
        • Lee J.S.
        • et al.
        A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
        J Natl Cancer Inst. 1994; 86: 673-680
        • Depierre A.
        • Milleron B.
        • Moro-Sibilot D.
        • Chevret S.
        • Quoix E.
        • Lebeau B.
        • et al.
        Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
        J Clin Oncol. 2002; 20: 247-253
        • Mattson K.V.
        • Abratt R.P.
        • ten Velde G.
        • Krofta K.
        Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
        Ann Oncol. 2003; 14: 116-122
        • Nagai K.
        • Tsuchiya R.
        • Mori T.
        • Tada H.
        • Ichinose Y.
        • Koike T.
        • et al.
        A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
        J Thorac Cardiovasc Surg. 2003; 125: 254-260
        • Rusch V.W.
        • Giroux D.J.
        • Kraut M.J.
        • Crowley J.
        • Hazuka M.
        • Winton T.
        • et al.
        Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
        J Clin Oncol. 2007; 25: 313-318
        • van Meerbeeck J.P.
        • Kramer G.W.
        • Van Schil P.E.
        • Legrand C.
        • Smit E.F.
        • Schramel F.
        • et al.
        Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
        J Natl Cancer Inst. 2007; 99: 442-450
        • Albain K.S.
        • Swann R.S.
        • Rusch V.W.
        • Turrisi I.I.I., A.T.
        • Shepherd F.A.
        • Smith C.
        • et al.
        Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
        Lancet. 2009; 374: 379-386
        • Girard N.
        • Mornex F.
        • Douillard J.Y.
        • Bossard N.
        • Quoix E.
        • Beckendorf V.
        • et al.
        Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
        Lung Cancer. 2010; 69: 86-93
        • Pisters K.M.
        • Vallières E.
        • Crowley J.J.
        • Franklin W.A.
        • Bunn Jr, P.A.
        • Ginsberg R.J.
        • et al.
        Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
        J Clin Oncol. 2010; 28: 1843-1849
        • Eberhardt W.E.
        • Pöttgen C.
        • Gauler T.C.
        • Veit S.
        • Heinreich V.
        • Welter S.
        • et al.
        Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB Non-Small-Cell Lung Cancer after Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
        J Clin Oncol. 2015; 33: 4194-4201
        • Betticher D.C.
        • Hsu Schmitz S.F.
        • Totsch M.
        • Hansen E.
        • Joss C.
        • von Briel C.
        • et al.
        Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
        J Clin Oncol. 2003; 21: 1752-1759
        • Stupp R.
        • Mayer M.
        • Kann R.
        • Weder W.
        • Zouhair A.
        • Betticher D.C.
        • et al.
        Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
        Lancet Oncol. 2009; 10: 785-793
        • Pless M.
        • Stupp R.
        • Ris H.B.
        • Stahel R.A.
        • Weder W.
        • Thierstein S.
        • et al.
        Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
        Lancet. 2015; 386: 1049-1056
      1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non--Small Cell Lung Cancer (Version 4.2021). 2021
        • Postmus P.E.
        • Kerr K.M.
        • Oudkerk M.
        • Senan S.
        • Waller D.A.
        • Vansteenkiste J.
        • et al.
        Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2017; 28: iv1-iv21
        • Kris M.G.
        • Gaspar L.E.
        • Chaft J.E.
        • Kennedy E.B.
        • Azzoli C.G.
        • Ellis P.M.
        • et al.
        Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
        J Clin Oncol. 2017; 35: 2960-2974
        • De Leyn P.
        • Lardinois D.
        • Van Schil P.E.
        • Rami-Porta R.
        • Passlick B.
        • Zielinksi M.
        • et al.
        ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.
        Eur J Cardiothorac Surg. 2007; 32: 1-8
        • Martini N.
        Mediastinal lymph node dissection for lung cancer. The Memorial experience.
        Chest Surg Clin N Am. 1995; 5: 189-203
        • Goldstraw P.
        • Chansky K.
        • Crowley J.
        • Rami-Porta R.
        • Asamura H.
        • Eberhardt W.E.E.
        • et al.
        The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer.
        J Thorac Oncol. 2016; 11: 39-51
        • Früh M.
        • Betticher D.C.
        • Stupp R.
        • Xyrafas A.
        • Peters S.
        • Ris H.B.
        • et al.
        Multimodal treatment in operable stage III NSCLC: a pooled analysis on long-term results of three SAKK trials (SAKK 16/96, 16/00, and 16/01).
        J Thorac Oncol. 2019; 14: 115-123
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Gottfried M.
        • Ramlau R.
        • Krzakowski M.
        • Ziolo G.
        • Olechnowicz H.
        • Koubkova L.
        • et al.
        Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.
        J Thorac Oncol. 2008; 3: 152-157
        • Donington J.S.
        • Paulus R.
        • Edelman M.J.
        • Krasna M.J.
        • Le Q.T.
        • Suntharalingam M.
        • et al.
        Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer.
        J Thorac Cardiovasc Surg. 2020; 160: 1331-1345.e1331
        • Rothschild S.
        • Zippelius A.
        • Eboulet E.I.
        • Savic Prince S.
        • Betticher D.C.
        • Bettini A.
        • et al.
        SAKK 16/14: anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—a multicenter single-arm phase II trial.
        J Clin Oncol. 2020; 38: 9016
        • Provencio M.
        • Nadal E.
        • Insa A.
        • García-Campelo M.R.
        • Casal-Rubio J.
        • Dómine M.
        • et al.
        Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2020; 21: 1413-1422
        • Forde P.M.
        • Chaft J.E.
        • Smith K.N.
        • Anagnostou V.
        • Cottrell T.R.
        • Hellmann M.D.
        • et al.
        Neoadjuvant PD-1 blockade in resectable lung cancer.
        N Engl J Med. 2018; 378: 1976-1986
        • Curioni-Fontecedro A.
        • Perentes J.Y.
        • Gelpke H.
        • Xyrafas A.
        • Bouchaab H.
        • Mach N.
        • et al.
        Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
        Br J Cancer. 2019; 120: 968-974
        • Yang C.J.
        • McSherry F.
        • Mayne N.R.
        • Wang X.
        • Berry M.F.
        • Tong B.
        • et al.
        Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer.
        Ann Thorac Surg. 2018; 105: 924-929
        • Cascone T.
        • Gold K.A.
        • Swisher S.G.
        • Liu D.D.
        • Fossella F.V.
        • Sepesi B.
        • et al.
        Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer.
        Ann Thorac Surg. 2018; 105: 418-424
        • Sun L.
        • Guo Y.J.
        • Song J.
        • Wang Y.R.
        • Zhang S.L.
        • Huang L.T.
        • et al.
        Neoadjuvant EGFR-TKI therapy for EGFR-mutant NSCLC: a systematic review and pooled analysis of five prospective clinical trials.
        Front Oncol. 2021; 10: 586596
        • Antonia S.J.
        • Villegas A.
        • Daniel D.
        • Vicente D.
        • Murakami S.
        • Hui R.
        • et al.
        Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.
        N Engl J Med. 2018; 379: 2342-2350
        • Steuer C.E.
        • Behera M.
        • Ernani V.
        • Higgins K.A.
        • Saba N.F.
        • Shin D.M.
        • et al.
        Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review.
        JAMA Oncol. 2017; 3: 1120-1129
        • Zhang Y.H.
        • Lu Y.
        • Lu H.
        • Zhou Y.M.
        Development of a survival prognostic model for non-small cell lung cancer.
        Front Oncol. 2020; 10: 362
        • Antonia S.J.
        • Villegas A.
        • Daniel D.
        • Vicente D.
        • Murakami S.
        • Hui R.
        • et al.
        Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.
        N Engl J Med. 2017; 377: 1919-1929